Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status?

Hye Lim Lee; Hung Youl Seok; Han Wook Ryu; Eun Bee Cho; Bong Chul Kim; Byoung Joon Kim; Ju Hong Min; Jin Myoung Seok; Ha Young Shin; Sa Yoon Kang; Oh Hyun Kwon; Sang Soo Lee; Jeeyoung Oh; Eun Hee Sohn; So Young Huh; Joong Yang Cho; Jae Young Seong; Byung Jo Kim

doi:10.1177/1352458519885489

Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status?

Hye Lim Lee, Hung Youl Seok, Han Wook Ryu, Eun Bee Cho, Bong Chul Kim, Byoung Joon Kim, Ju Hong Min, Jin Myoung Seok, Ha Young Shin, Sa Yoon Kang, Oh Hyun Kwon, Sang Soo Lee, Jeeyoung Oh, Eun Hee Sohn, So Young Huh, Joong Yang Cho, Jae Young Seong, Byung Jo Kim

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Background: Neuromyelitis optica spectrum disorder (NMOSD) targets astrocytes and elevates the levels of astrocyte-injury markers during attacks. FAM19A5, involved in reactive gliosis, is secreted by reactive astrocytes following central nervous system (CNS) damage. Objective: To investigate the significance of serum FAM19A5 in patients with NMOSD. Methods: We collected clinical data and sera of 199 patients from 11 hospitals over 21 months. FAM19A5 levels were compared among three groups: NMOSD with positive anti-aquaporin-4 antibody (NMOSD-AQP4), other CNS demyelinating disease, and healthy controls. Results: The median serum FAM19A5 level was higher in the NMOSD-AQP4 (4.90 ng/mL (3.95, 5.79)) than in the other CNS demyelinating (2.35 ng/mL (1.83, 4.07), p < 0.001) or healthy control (1.02 ng/mL (0.92, 1.14), p < 0.001) groups. There were significant differences in the median serum FAM19A5 levels between the attack and remission periods (5.89 ng/mL (5.18, 6.98); 4.40 ng/mL (2.72, 5.13), p < 0.001) in the NMOSD-AQP4 group. Sampling during an attack (p < 0.001) and number of past attacks (p = 0.010) were independently associated with increased serum FAM19A5. Conclusion: Serum FAM19A5 was higher in patients with NMOSD-AQP4 and correlated with clinical characteristics. Thus, serum FAM19A5 may be a novel clinical biomarker for NMOSD-AQP4.

Original language	English
Pages (from-to)	1700-1707
Number of pages	8
Journal	Multiple Sclerosis Journal
Volume	26
Issue number	13
DOIs	https://doi.org/10.1177/1352458519885489
Publication status	Published - 2020 Nov 1

Bibliographical note

Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Korean Centers for Disease Control and Prevention (No. 2017E6300202) and by a grant from the National Research Foundation of Korea (NRF2017R1A2B4006975).

Publisher Copyright:
© The Author(s), 2019.

Keywords

CNS demyelinating disease
FAM19A5
MOG associated disease
Neuromyelitis optica spectrum disorder
astrocyte
reactive gliosis

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1177/1352458519885489

Cite this

Lee, H. L., Seok, H. Y., Ryu, H. W., Cho, E. B., Kim, B. C., Kim, B. J., Min, J. H., Seok, J. M., Shin, H. Y., Kang, S. Y., Kwon, O. H., Lee, S. S., Oh, J., Sohn, E. H., Huh, S. Y., Cho, J. Y., Seong, J. Y., & Kim, B. J. (2020). Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status? Multiple Sclerosis Journal, 26(13), 1700-1707. https://doi.org/10.1177/1352458519885489

Lee, HL, Seok, HY, Ryu, HW, Cho, EB, Kim, BC, Kim, BJ, Min, JH, Seok, JM, Shin, HY, Kang, SY, Kwon, OH, Lee, SS, Oh, J, Sohn, EH, Huh, SY, Cho, JY, Seong, JY & Kim, BJ 2020, 'Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status?', Multiple Sclerosis Journal, vol. 26, no. 13, pp. 1700-1707. https://doi.org/10.1177/1352458519885489

@article{ab547961dfc8442180ac69d3e4e78f5b,

title = "Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status?",

abstract = "Background: Neuromyelitis optica spectrum disorder (NMOSD) targets astrocytes and elevates the levels of astrocyte-injury markers during attacks. FAM19A5, involved in reactive gliosis, is secreted by reactive astrocytes following central nervous system (CNS) damage. Objective: To investigate the significance of serum FAM19A5 in patients with NMOSD. Methods: We collected clinical data and sera of 199 patients from 11 hospitals over 21 months. FAM19A5 levels were compared among three groups: NMOSD with positive anti-aquaporin-4 antibody (NMOSD-AQP4), other CNS demyelinating disease, and healthy controls. Results: The median serum FAM19A5 level was higher in the NMOSD-AQP4 (4.90 ng/mL (3.95, 5.79)) than in the other CNS demyelinating (2.35 ng/mL (1.83, 4.07), p < 0.001) or healthy control (1.02 ng/mL (0.92, 1.14), p < 0.001) groups. There were significant differences in the median serum FAM19A5 levels between the attack and remission periods (5.89 ng/mL (5.18, 6.98); 4.40 ng/mL (2.72, 5.13), p < 0.001) in the NMOSD-AQP4 group. Sampling during an attack (p < 0.001) and number of past attacks (p = 0.010) were independently associated with increased serum FAM19A5. Conclusion: Serum FAM19A5 was higher in patients with NMOSD-AQP4 and correlated with clinical characteristics. Thus, serum FAM19A5 may be a novel clinical biomarker for NMOSD-AQP4.",

keywords = "CNS demyelinating disease, FAM19A5, MOG associated disease, Neuromyelitis optica spectrum disorder, astrocyte, reactive gliosis",

author = "Lee, {Hye Lim} and Seok, {Hung Youl} and Ryu, {Han Wook} and Cho, {Eun Bee} and Kim, {Bong Chul} and Kim, {Byoung Joon} and Min, {Ju Hong} and Seok, {Jin Myoung} and Shin, {Ha Young} and Kang, {Sa Yoon} and Kwon, {Oh Hyun} and Lee, {Sang Soo} and Jeeyoung Oh and Sohn, {Eun Hee} and Huh, {So Young} and Cho, {Joong Yang} and Seong, {Jae Young} and Kim, {Byung Jo}",

note = "Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Korean Centers for Disease Control and Prevention (No. 2017E6300202) and by a grant from the National Research Foundation of Korea (NRF2017R1A2B4006975). Publisher Copyright: {\textcopyright} The Author(s), 2019.",

year = "2020",

month = nov,

day = "1",

doi = "10.1177/1352458519885489",

language = "English",

volume = "26",

pages = "1700--1707",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "13",

}

TY - JOUR

T1 - Serum FAM19A5 in neuromyelitis optica spectrum disorders

T2 - Can it be a new biomarker representing clinical status?

AU - Lee, Hye Lim

AU - Seok, Hung Youl

AU - Ryu, Han Wook

AU - Cho, Eun Bee

AU - Kim, Bong Chul

AU - Kim, Byoung Joon

AU - Min, Ju Hong

AU - Seok, Jin Myoung

AU - Shin, Ha Young

AU - Kang, Sa Yoon

AU - Kwon, Oh Hyun

AU - Lee, Sang Soo

AU - Oh, Jeeyoung

AU - Sohn, Eun Hee

AU - Huh, So Young

AU - Cho, Joong Yang

AU - Seong, Jae Young

AU - Kim, Byung Jo

N1 - Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Korean Centers for Disease Control and Prevention (No. 2017E6300202) and by a grant from the National Research Foundation of Korea (NRF2017R1A2B4006975). Publisher Copyright: © The Author(s), 2019.

PY - 2020/11/1

Y1 - 2020/11/1

N2 - Background: Neuromyelitis optica spectrum disorder (NMOSD) targets astrocytes and elevates the levels of astrocyte-injury markers during attacks. FAM19A5, involved in reactive gliosis, is secreted by reactive astrocytes following central nervous system (CNS) damage. Objective: To investigate the significance of serum FAM19A5 in patients with NMOSD. Methods: We collected clinical data and sera of 199 patients from 11 hospitals over 21 months. FAM19A5 levels were compared among three groups: NMOSD with positive anti-aquaporin-4 antibody (NMOSD-AQP4), other CNS demyelinating disease, and healthy controls. Results: The median serum FAM19A5 level was higher in the NMOSD-AQP4 (4.90 ng/mL (3.95, 5.79)) than in the other CNS demyelinating (2.35 ng/mL (1.83, 4.07), p < 0.001) or healthy control (1.02 ng/mL (0.92, 1.14), p < 0.001) groups. There were significant differences in the median serum FAM19A5 levels between the attack and remission periods (5.89 ng/mL (5.18, 6.98); 4.40 ng/mL (2.72, 5.13), p < 0.001) in the NMOSD-AQP4 group. Sampling during an attack (p < 0.001) and number of past attacks (p = 0.010) were independently associated with increased serum FAM19A5. Conclusion: Serum FAM19A5 was higher in patients with NMOSD-AQP4 and correlated with clinical characteristics. Thus, serum FAM19A5 may be a novel clinical biomarker for NMOSD-AQP4.

AB - Background: Neuromyelitis optica spectrum disorder (NMOSD) targets astrocytes and elevates the levels of astrocyte-injury markers during attacks. FAM19A5, involved in reactive gliosis, is secreted by reactive astrocytes following central nervous system (CNS) damage. Objective: To investigate the significance of serum FAM19A5 in patients with NMOSD. Methods: We collected clinical data and sera of 199 patients from 11 hospitals over 21 months. FAM19A5 levels were compared among three groups: NMOSD with positive anti-aquaporin-4 antibody (NMOSD-AQP4), other CNS demyelinating disease, and healthy controls. Results: The median serum FAM19A5 level was higher in the NMOSD-AQP4 (4.90 ng/mL (3.95, 5.79)) than in the other CNS demyelinating (2.35 ng/mL (1.83, 4.07), p < 0.001) or healthy control (1.02 ng/mL (0.92, 1.14), p < 0.001) groups. There were significant differences in the median serum FAM19A5 levels between the attack and remission periods (5.89 ng/mL (5.18, 6.98); 4.40 ng/mL (2.72, 5.13), p < 0.001) in the NMOSD-AQP4 group. Sampling during an attack (p < 0.001) and number of past attacks (p = 0.010) were independently associated with increased serum FAM19A5. Conclusion: Serum FAM19A5 was higher in patients with NMOSD-AQP4 and correlated with clinical characteristics. Thus, serum FAM19A5 may be a novel clinical biomarker for NMOSD-AQP4.

KW - CNS demyelinating disease

KW - FAM19A5

KW - MOG associated disease

KW - Neuromyelitis optica spectrum disorder

KW - astrocyte

KW - reactive gliosis

UR - http://www.scopus.com/inward/record.url?scp=85074841378&partnerID=8YFLogxK

U2 - 10.1177/1352458519885489

DO - 10.1177/1352458519885489

M3 - Article

C2 - 31680620

AN - SCOPUS:85074841378

SN - 1352-4585

VL - 26

SP - 1700

EP - 1707

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 13

ER -

Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status?

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this